Brian T. Hill, MD, PhD

Articles

Mechanism and Frontline Use of BTK Inhibitors in CLL

July 14th 2023

Brian T. Hill, MD, Ph.D., and Paulo Gia, MD explain the mechanism of action of BTK inhibitors and the rationale behind their use in chronic lymphocytic leukemia (CLL).

Closing Remarks on Unmet Needs in R/R FL

November 10th 2022

Dr Hill closes by discussing current unmet needs in the R/R FL landscape and giving practical advice to providers caring for patients with FL.

CAR T-cell Options for Patients with R/R FL

November 10th 2022

A focused discussion on available CAR T-cell therapies for patients with R/R FL, supporting efficacy data, and how these therapies have impacted the field.

Considerations for Treatment Selection in the Third-Line R/R FL Setting

November 3rd 2022

Dr Hill shares how he would have handled the patient case and discusses factors that contribute to treatment selection among third-line therapies for patients with R/R FL, including axicabtagene ciloleucel and other CAR T-cell therapies.

Typical Treatment Responses in Patients with FL and Incidence of Relapsed or Refractory Disease

November 3rd 2022

Insights concerning typical treatment responses experienced by patients with FL, clinical factors that may be predictive of response, and the incidence of relapsed or refractory disease.

First-, Second-, and Third-Line Treatment Selection for a FL Patient Case

October 27th 2022

Dr Hill continues his discussion of the case, outlining the first-, second, and third-line treatment strategies employed for this particular patient.

Follicular Lymphoma Background and Introduction to a Patient Case

October 27th 2022

Brian T. Hill, MD, PhD briefly reviews the diagnosis and staging of FL, typical prognoses for patients with the disease, and begins to outline a patient case of R/R FL.

Clinical Pearls in the Management of Marginal Zone Lymphoma

February 25th 2022

Closing out their discussion on B-cell malignancies, expert panelists share clinical pearls on the management of marginal zone lymphoma.

Novel Treatment Strategies for Relapsed/Refractory MZL

February 25th 2022

A comprehensive review of novel therapies in relapsed/refractory marginal zone lymphoma and possible sequencing strategies in this setting.

Frontline Treatment Options for Marginal Zone Lymphoma

February 18th 2022

Shared insight on frontline treatment approaches for patients diagnosed with marginal zone lymphoma.

Clinical Pearls in the Management of Follicular Lymphoma

February 18th 2022

Clinical pearls for community physicians regarding the optimal management of patients with follicular lymphoma.

Optimizing the Sequencing of Therapy in Follicular Lymphoma

February 11th 2022

Panelists use an illustrative clinical case to comprehensively discuss the selection and sequencing of therapies for patients with follicular lymphoma.

PI3K Inhibitors in Relapsed/Refractory Follicular Lymphoma

February 11th 2022

A review of the role of PI3K inhibitors in the treatment of follicular lymphoma, and how they have been used to improve patient outcomes.

Dr. Hill on the Potential Utility of Next-Generation PI3K Inhibitors in CLL

February 9th 2022

Brian T. Hill, MD, PhD, discusses the potential utility of next-generation PI3K inhibitors in chronic lymphocytic leukemia.

Novel Therapies and Treatment Selection in Patients With Relapsed/Refractory FL

February 4th 2022

Expert perspectives on novel approaches to treatment in the relapsed/refractory setting, particularly CAR T-cell therapy, for patients with follicular lymphoma.

Pathophysiology of Follicular Lymphoma and Frontline Therapy

February 4th 2022

Shared insight on the indolent nature of follicular lymphoma and frontline therapy options for this disease.

Clinical Pearls in the Management of Mantle Cell Lymphoma

January 28th 2022

Closing out their discussion on mantle cell lymphoma, expert panelists share clinical pearls for practicing community physicians.

Optimizing MCL Management: Sequencing and Combination Strategies

January 28th 2022

Panelists use an illustrative clinical case to highlight best practices in sequencing therapy for mantle cell lymphoma and discuss novel combination strategies under investigation.

CAR T-cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma

January 21st 2022

A brief review of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma as studied in the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Second-Line Therapy for MCL: Differentiating Available BTK Inhibitors

January 21st 2022

Moving to second-line therapy for mantle cell lymphoma, experts discuss available BTK inhibitors, including the novel agent pirtobrutinib.